Elagolix Treatment for Up to 12 Months in Women With Heavy Menstrual Bleeding and Uterine Leiomyomas
Sign Up to like & getrecommendations! Published in 2020 at "Obstetrics and Gynecology"
DOI: 10.1097/aog.0000000000003869
Abstract: Up to 12 months of elagolix with add-back therapy provided sustained reduction in menstrual blood loss with an acceptable safety profile in women with uterine leiomyomas. read more here.
Keywords: women heavy; uterine leiomyomas; elagolix treatment; heavy menstrual ... See more keywords